Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (12652)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Apr 21, 2016 (publication date) through Jul 6, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Li J, Hou Y, Cai XB, Liu B. Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma. World J Gastroenterol 2016; 22(15): 4034-4040 [PMID: 27099447 DOI: 10.3748/wjg.v22.i15.4034] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v22/i15/4034.htm |
| Number | Citing Articles |
| 1 |
Yoh Asahi, Tatsuhiko Kakisaka, Toshiya Kamiyama, Tatsuya Orimo, Shingo Shimada, Akihisa Nagatsu, Takeshi Aiyama, Yuzuru Sakamoto, Kazuki Wakizaka, Shunsuke Shichi, Hirofumi Kamachi, Akinobu Taketomi. Improved survival outcome of curative liver resection for Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma in the era of tyrosine kinase inhibitors. Hepatology Research 2025; 55(1): 69 doi: 10.1111/hepr.14098
|
| 2 |
Ao Huang, Xin-Rong Yang, Wen-Yuan Chung, Ashley R. Dennison, Jian Zhou. Targeted therapy for hepatocellular carcinoma. Signal Transduction and Targeted Therapy 2020; 5(1) doi: 10.1038/s41392-020-00264-x
|
| 3 |
Lucia Cerrito, Brigida Eleonora Annicchiarico, Roberto Iezzi, Antonio Gasbarrini, Maurizio Pompili, Francesca Romana Ponziani. Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers. World Journal of Gastroenterology 2019; 25(31): 4360-4382 doi: 10.3748/wjg.v25.i31.4360
|
| 4 |
Jian-Hong Zhong, Xue-Ke Du, Bang-De Xiang, Le-Qun Li. Adjuvant sorafenib in hepatocellular carcinoma: A cautionary comment of STORM trial. World Journal of Hepatology 2016; 8(23): 957-960 doi: 10.4254/wjh.v8.i23.957
|
| 5 |
Han Ah Lee, Chai Hong Rim. Efficacy of Local Treatments for Hepatocellular Carcinoma Involving the Inferior Vena Cava and/or Right Atrium. Journal of Hepatocellular Carcinoma 2020; : 435 doi: 10.2147/JHC.S285357
|
| 6 |
Jian Li, Wen-qiang Wang, Rong-hua Zhu, Xing Lv, Jin-lin Wang, Bin-yong Liang, Er-lei Zhang, Zhi-yong Huang. Postoperative adjuvant tyrosine kinase inhibitors combined with anti-PD-1 antibodies improves surgical outcomes for hepatocellular carcinoma with high-risk recurrent factors. Frontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1202039
|
| 7 |
Xu Feng, Guo-Ying Feng, Jie Tao, Yu-Pei Ao, Xin-Hua Wu, Shi-Guai Qi, Zheng-Rong Shi. Comparison of different adjuvant therapy regimen efficacies in patients with high risk of recurrence after radical resection of hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology 2023; 149(12): 10505 doi: 10.1007/s00432-023-04874-0
|
| 8 |
Kuan-Chun Hsueh, Cheng-Chun Lee, Pi-Teh Huang, Chih-Yu Liang, Shun-Fa Yang. Survival Benefit of Experience of Liver Resection for Advanced Recurrent Hepatocellular Carcinoma Treated with Sorafenib: A Propensity Score Matching Analysis. Current Oncology 2023; 30(3): 3206 doi: 10.3390/curroncol30030243
|
| 9 |
Feng Che, Yi Wei, Qing Xu, Qian Li, Tong Zhang, Li-Ye Wang, Man Li, Fang Yuan, Bin Song. Noninvasive identification of SOX9 status using radiomics signatures may help construct personalized treatment strategy in hepatocellular carcinoma. Abdominal Radiology 2024; 49(9): 3024 doi: 10.1007/s00261-024-04190-2
|
| 10 |
Kazuhiko Sakamoto, Hiroaki Nagano. Surgical treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus. Hepatology Research 2017; 47(10): 957 doi: 10.1111/hepr.12923
|
| 11 |
Riccardo Nevola, Augusto Delle Femine, Valerio Rosato, Loreta Anesti Kondili, Maria Alfano, Davide Mastrocinque, Simona Imbriani, Pasquale Perillo, Domenico Beccia, Angela Villani, Rachele Ruocco, Livio Criscuolo, Marco La Montagna, Antonio Russo, Aldo Marrone, Ferdinando Carlo Sasso, Raffaele Marfella, Luca Rinaldi, Nicolino Esposito, Giuseppe Barberis, Ernesto Claar. Neoadjuvant and Adjuvant Systemic Therapies in Loco-Regional Treatments for Hepatocellular Carcinoma: Are We at the Dawn of a New Era?. Cancers 2023; 15(11): 2950 doi: 10.3390/cancers15112950
|
| 12 |
Wang Gu, Zhong Tong. Sorafenib in the treatment of patients with hepatocellular carcinoma (HCC) and microvascular infiltration: a systematic review and meta-analysis. Journal of International Medical Research 2020; 48(8) doi: 10.1177/0300060520946872
|
| 13 |
Philipp Heumann, Andreas Albert, Karsten Gülow, Deniz Tümen, Martina Müller, Arne Kandulski. Insights in Molecular Therapies for Hepatocellular Carcinoma. Cancers 2024; 16(10): 1831 doi: 10.3390/cancers16101831
|
| 14 |
Lin Zheng, Chen-Yang Guo, Cheng-Shi Chen, Jin-Cheng Xiao, Hong-Tao Hu, Hong-Tao Cheng, Deng-Wei Zong, Li Jiang, Hai-Liang Li. Sorafenib improves lipiodol deposition in transarterial chemoembolization of Chinese patients with hepatocellular carcinoma: a long-term, retrospective study. Oncotarget 2017; 8(57): 97613 doi: 10.18632/oncotarget.18811
|
| 15 |
Valentina Zanuso, Lorenza Rimassa, Chiara Braconi. The rapidly evolving landscape of HCC: Selecting the optimal systemic therapy. Hepatology 2025; 81(4): 1365 doi: 10.1097/HEP.0000000000000572
|
| 16 |
Masataka Amisaki, Hiroaki Saito, Naruo Tokuyasu, Teruhisa Sakamoto, Soichiro Honjo, Yoshiyuki Fujiwara. Prognostic value of postoperative complication for early recurrence after curative resection of hepatocellular carcinoma. Hepatobiliary & Pancreatic Diseases International 2018; 17(4): 323 doi: 10.1016/j.hbpd.2018.03.016
|
| 17 |
雪瑞 房. Retrospective Efficacy and Safety Analysis
of Prophylactic Transarterial
Chemoembolization (TACE) and Targeted Immunotherapy after Primary Liver Cancer Resection. Journal of Clinical Personalized Medicine 2025; 4(03): 568 doi: 10.12677/jcpm.2025.43382
|
| 18 |
Lei Wang, Chunhong Xiao, Ren Wang, Jingbo Chen, Weiping Zhou, Jingfeng Liu, Nanping Lin, Kongying Lin. The Clinical Value of Postoperative Transarterial Chemoembolization for Resectable Patients with Intermediate Hepatocellular Carcinoma After Radical Hepatectomy: a Propensity Score-Matching Study. Journal of Gastrointestinal Surgery 2021; 25(5): 1172 doi: 10.1007/s11605-020-04588-5
|
| 19 |
Sha She, Jinzhi Shi, Jiling Zhu, Fan Yang, Jia Yu, Kai Dai. Impact of inflammation and the immune system on hepatocellular carcinoma recurrence after hepatectomy. Cancer Medicine 2024; 13(4) doi: 10.1002/cam4.7018
|
| 20 |
Han Ah Lee, Yeon Seok Seo, In-Soo Shin, Won Sup Yoon, Hye Yoon Lee, Chai Hong Rim. Efficacy and feasibility of surgery and external radiotherapy for hepatocellular carcinoma with portal invasion: A meta-analysis. International Journal of Surgery 2022; 104: 106753 doi: 10.1016/j.ijsu.2022.106753
|
| 21 |
Qingli Li, Tianqiang Song. Association Between Adjuvant Sorafenib and the Prognosis of Patients With Hepatocellular Carcinoma at a High Risk of Recurrence After Radical Resection. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.633033
|
| 22 |
Hiroto Matsui Matsui, Shoichi Hazama, Masao Nakajima, Ming Xu, Satoshi Matsukuma, Yukio Tokumitsu, Yoshitaro Shindo, Shinobu Tomochika, Shin Yoshida, Michihisa Iida, Nobuaki Suzuki, Shigeru Takeda, Shigefumi Yoshino, Tomio Ueno, Masaaki Oka, Hiroaki Nagano. Novel adjuvant dendritic cell therapy with transfection of heat-shock protein 70 messenger RNA for patients with hepatocellular carcinoma: a phase I/II prospective randomized controlled clinical trial. Cancer Immunology, Immunotherapy 2021; 70(4): 945 doi: 10.1007/s00262-020-02737-y
|
| 23 |
Jianming Yang, Shijie Jiang, Yewu Chen, Jian Zhang, Yinan Deng. Adjuvant ICIs Plus Targeted Therapies Reduce HCC Recurrence after Hepatectomy in Patients with High Risk of Recurrence. Current Oncology 2023; 30(2): 1708 doi: 10.3390/curroncol30020132
|
| 24 |
G.K. Glantzounis, A. Paliouras, M.-C. Stylianidi, H. Milionis, P. Tzimas, D. Roukos, G. Pentheroudakis, E. Felekouras. The role of liver resection in the management of intermediate and advanced stage hepatocellular carcinoma. A systematic review. European Journal of Surgical Oncology 2018; 44(2): 195 doi: 10.1016/j.ejso.2017.11.022
|
| 25 |
Zun-Yi Zhang, Er-Lei Zhang, Bi-Xiang Zhang, Xiao-Ping Chen, Wei Zhang. Treatment for hepatocellular carcinoma with tumor thrombosis in the hepatic vein or inferior vena cava: A comprehensive review. World Journal of Gastrointestinal Surgery 2021; 13(8): 796-805 doi: 10.4240/wjgs.v13.i8.796
|
| 26 |
Yifei Tan, Qing Xu, Zhenru Wu, Wei Zhang, Bo Li, Bohan Zhang, Xi Xu, Bo Zhang, Ke Yan, Jiulin Song, Tao Lv, Jian Yang, Li Jiang, Yujun Shi, Jiayin Yang, Lunan Yan. Overexpression of PD-L1 is an Independent Predictor for Recurrence in HCC Patients Who Receive Sorafenib Treatment After Surgical Resection. Frontiers in Oncology 2022; 11 doi: 10.3389/fonc.2021.783335
|
| 27 |
Wei Zhang, Bixiang Zhang, Xiao-ping Chen. Adjuvant treatment strategy after curative resection for hepatocellular carcinoma. Frontiers of Medicine 2021; 15(2): 155 doi: 10.1007/s11684-021-0848-3
|
| 28 |
Zhi-Ming Zeng, Ning Mo, Jie Zeng, Fu-Chao Ma, Yan-Feng Jiang, Hua-Sheng Huang, Xi-Wen Liao, Guang-Zhi Zhu, Jie Ma, Tao Peng. Advances in postoperative adjuvant therapy for primary liver cancer. World Journal of Gastrointestinal Oncology 2022; 14(9): 1604-1621 doi: 10.4251/wjgo.v14.i9.1604
|
| 29 |
Jeng-Shiun Du, Shih-Hsien Hsu, Shen-Nien Wang. The Current and Prospective Adjuvant Therapies for Hepatocellular Carcinoma. Cancers 2024; 16(7): 1422 doi: 10.3390/cancers16071422
|
| 30 |
Jin Shang, Shanling Xu, Jiaxing Zhang, Xuting Ran, Lang Bai, Hong Tang. Efficacy of sorafenib in patients with hepatocellular carcinoma after resection: a meta-analysis. Oncotarget 2017; 8(65): 109723 doi: 10.18632/oncotarget.21299
|
| 31 |
Bin Guo, Qian Chen, Zhicheng Liu, Xiaoping Chen, Peng Zhu. Adjuvant therapy following curative treatments for hepatocellular carcinoma: current dilemmas and prospects. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1098958
|
| 32 |
Shenglan Huang, Dan Li, LingLing Zhuang, Liying Sun, Jianbing Wu. A meta-analysis of the efficacy and safety of adjuvant sorafenib for hepatocellular carcinoma after resection. World Journal of Surgical Oncology 2021; 19(1) doi: 10.1186/s12957-021-02280-9
|
| 33 |
Shashank Kumar, Abhay Kumar Pandey. Potential Molecular Targeted Therapy for Unresectable Hepatocellular Carcinoma. Current Oncology 2023; 30(2): 1363 doi: 10.3390/curroncol30020105
|
| 34 |
Jiang Li, Fan Yang, Jian Li, Zhi-Yong Huang, Qi Cheng, Er-Lei Zhang. Postoperative adjuvant therapy for hepatocellular carcinoma with microvascular invasion. World Journal of Gastrointestinal Surgery 2023; 15(1): 19-31 doi: 10.4240/wjgs.v15.i1.19
|
| 35 |
Sarwat Fatima, Nikki Pui-Yue Lee, Hiu Yee Kwan, Zhao Xiang Bian. Hepatocellular Carcinoma - Advances in Diagnosis and Treatment. 2018; doi: 10.5772/intechopen.71480
|
| 36 |
Zun-Yi Zhang, Er-Lei Zhang, Bi-Xiang Zhang, Wei Zhang. Surgery for hepatocellular carcinoma with tumor thrombosis in inferior vena cava: A case report. World Journal of Clinical Cases 2021; 9(36): 11495-11503 doi: 10.12998/wjcc.v9.i36.11495
|
| 37 |
Chen Jue, Wu Zhifeng, Zhang Zhisheng, Cui Lin, Qian Yayun, Jin Feng, Gu Hao, Ishikawa Shintaro, Tadashi Hisamitsu, Guo Shiyu, Liu Yanqing. Vasculogenic mimicry in hepatocellular carcinoma contributes to portal vein invasion. Oncotarget 2016; 7(47): 77987 doi: 10.18632/oncotarget.12867
|
| 38 |
Chang-Zhi Chen, Jian-Hong Zhong, Ya-Peng Qi, Jie Zhang, Tao Huang, Liang Ma, Le-Qun Li, Tao Peng, Bang-De Xiang. Development of a preoperative prognostic scoring system to predict benefits of hepatic resection in advanced hepatocellular carcinoma patients. Bioscience Reports 2021; 41(4) doi: 10.1042/BSR20201928
|
| 39 |
Zi-Wen Tao, Bao-Quan Cheng, Tao Zhou, Yan-Jing Gao. Management of hepatocellular carcinoma patients with portal vein tumor thrombosis: A narrative review. Hepatobiliary & Pancreatic Diseases International 2022; 21(2): 134 doi: 10.1016/j.hbpd.2021.12.004
|